

feet msl elevation of the flare deck. Approximately 420 columns/piles will be installed to support the earthen embankment of the road. Approximately 16,800 cubic yards of sandy/clay material will be used for the embankment and an additional 1,030 cubic yards of grout will be used for the columns/piles.

**CMP Project No:** 16-1238-F1

**Type of Application:** U.S. Army Corps of Engineers (USACE) permit application #SWG-2007-00083. This application will be reviewed pursuant to Section 404 of the Clean Water Act.

**Note: The consistency review for this project may be conducted by the Texas Commission on Environmental Quality under §401 of the Clean Water Act (33 U.S.C.A. §1344).**

**Applicant:** Enterprise Products Operating LLC

**Location:** The project site is located in wetlands adjacent to the Houston Ship Channel (Buffalo Bayou), approximately 0.8-mile east of Sam Houston Parkway and immediately south of and adjacent to Jacintoport Boulevard, in Harris County, Texas. The project can be located on the U.S.G.S. quadrangle map titled: Pasadena and Jacinto City, Texas.

**LATITUDE & LONGITUDE (NAD 83):**

Latitude: 29.747844° North; Longitude: 95.132055° West

**Project Description:** The applicant proposes to place fill material into 1.43 acres of wetlands for the construction of eight 217-foot diameter above-ground tanks on a 38.6-acre tract immediately adjacent to their existing facility. Construction of the project will consist of clearing vegetation, excavating, filling and grading the topography as necessary to provide suitable foundation for the facility construction. The project would impact 0.457 acre of scrub/shrub wetlands and 0.978 acre of forested wetlands for a total proposed impact of 1.43 acres. The wetland fill would allow expansion of the applicant's existing oil tank farm for the purpose of increasing the storage capacity. The applicant's plans are enclosed in four sheets.

**CMP Project No:** 16-1024-F1

**Type of Application:** U.S. Army Corps of Engineers (USACE) permit application #SWG-2015-00106. This application will be reviewed pursuant to Section 404 of the Clean Water Act.

Pursuant to §306(d)(14) of the Coastal Zone Management Act of 1972 (16 U.S.C.A. §§1451 - 1464), as amended, interested parties are invited to submit comments on whether a proposed action or activity is or is not consistent with the Texas Coastal Management Program goals and policies and whether the action should be referred to the Land Commissioner for review.

Further information on the applications listed above, including a copy of the consistency certifications or consistency determinations for inspection, may be obtained from Mr. Ray Newby, P.O. Box 12873, Austin, Texas 78711-2873 or via email at [federal.consistency@glo.texas.gov](mailto:federal.consistency@glo.texas.gov). Comments should be sent to Mr. Newby at the above address or by email.

TRD-201601376

Anne L. Idsal

Chief Clerk/Deputy Land Commissioner

General Land Office

Filed: March 23, 2016

**Texas Health and Human Services Commission**

Notice of Public Hearing on Proposed Payment Rates for the Comprehensive Rehabilitation Services Program

**Hearing.** The Texas Health and Human Services Commission (HHSC) will conduct a public hearing on Tuesday, April 12, 2016, at 9:00 a.m. to receive public comment on proposed new payment rates for the Comprehensive Rehabilitation Services (CRS) program operated by the Department of Assistive and Rehabilitative Services.

The hearing will be held in compliance with 1 Texas Administrative Code (TAC) §355.105(g)(1), which requires public notice and hearings on proposed reimbursement rates before HHSC approves the proposed rates. The public hearing will be held in the Public Hearing Room of the Winters Building, located at 701 West 51st St., Austin, Texas. Entry is through Security at the north entrance to the building. Persons requiring Americans with Disabilities Act accommodation or auxiliary aids or services should contact Rate Analysis by calling (512) 730-7401 at least 72 hours prior to the hearing so appropriate arrangements can be made.

**Proposal.** HHSC proposes new payment rates for the CRS program. The proposed rates will be effective September 1, 2016, and were determined in accordance with the rate-setting methodologies listed below under "Methodology and Justification."

**Methodology and Justification.** The proposed rates were determined in accordance with the rate-setting methodologies that will be codified at 1 TAC Chapter 355, Subchapter M, §355.9040, Reimbursement Methodology for the Comprehensive Rehabilitation Services Program. The proposed new rule will be published in the April 29th edition of the *Texas Register* and is scheduled to be adopted effective September 1, 2016.

**Briefing Package.** A briefing package describing the proposed rates will be available at <http://www.hhsc.state.tx.us/rad/rate-packets.shtml> on April 1, 2016. Interested parties may also obtain a copy of the briefing package prior to the hearing by contacting Rate Analysis by telephone at (512) 730-7401; by fax at (512) 730-7475; or by e-mail at [RAD-LTSS@hhsc.state.tx.us](mailto:RAD-LTSS@hhsc.state.tx.us). The briefing package also will be available at the public hearing.

**Written Comments.** Written comments regarding the proposed rates may be submitted in lieu of, or in addition to, oral testimony until 5:00 p.m. the day of the hearing. Written comments may be sent by U.S. mail to Health and Human Services Commission, Attention: Rate Analysis, Mail Code H-400, P.O. Box 149030, Austin, Texas 78714-9030; by fax to Rate Analysis at (512) 730-7475; or by e-mail to [RAD-LTSS@hhsc.state.tx.us](mailto:RAD-LTSS@hhsc.state.tx.us). In addition, written comments may be sent by overnight mail or hand delivered to HHSC, Attention: Rate Analysis, Mail Code H-400, Brown Heatly Building, 4900 North Lamar Boulevard, Austin, Texas 78751-2399.

TRD-201601374

Karen Ray

Chief Counsel

Texas Health and Human Services Commission

Filed: March 23, 2016

**Department of State Health Services**

Amendment to the Texas Controlled Substances Schedule

This amendment to the Texas Schedules of Controlled Substances was signed by the Commissioner of the Department of State Health Services, and it will take effect 21 days following publication of this notice in the *Texas Register*.

The Administrator of the Drug Enforcement Administration (DEA) issued a final order placing N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (com-

mon names: MAB-CHMINACA and ABD-CHMINACA) and its optical, positional, and geometric isomers, salts and salts of isomers into Schedule I pursuant to the temporary scheduling provisions of the United States Controlled Substances Act (CSA) effective February 5, 2016. This final order was published in the Federal Register, Volume 81, Number 24, pages 6171 - 6175. The Administrator has taken action based on the following.

1. MAB-CHMINACA has a high potential for abuse;
2. MAB-CHMINACA has no currently accepted medical use in treatment in the United States; and,
3. There is a lack of accepted safety for use under medical supervision.

Pursuant to §481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced actions were published in the Federal Register; and, in the capacity as Commissioner of the Texas Department of State Health Services, John Hellerstedt, M.D., does hereby order that the substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (common names: MAB-CHMINACA and ABD-CHMINACA) be placed temporarily into Schedule I.

#### SCHEDULE I

Schedule I consists of:

-Schedule I opiates

\*\*\*

-Schedule I opium derivatives

\*\*\*

-Schedule I hallucinogenic substances

\*\*\*

-Schedule I stimulants

\*\*\*

-Schedule I depressants

\*\*\*

-Schedule I Cannabimimetic agents

\*\*\*

-Schedule I temporarily listed substances subject to emergency scheduling by the United States Drug Enforcement Administration.

\*Unless specifically excepted or unless listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following substances or that contains any of the substance's salts, isomers, and salts of isomers if the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation.

1. (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (Other names: UR-144 and 1-pentyl-3-(2,2,3,3-tetramethylcyclopropyl)indole);
2. [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (Other names: 5-fluoro-UR-144 and 5-F-UR-144 and XLR11 and 1-(5-fluoro-pentyl)-3-(2,2,3,3-tetramethylcyclopropyl)indole);
3. N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (Other names: APINACA, AKB48);

4. 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
5. 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
6. 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
7. Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: PB-22; QUPIC);
8. Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 5-fluoro-PB-22; 5F-PB-22);
9. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other name: AB-FUBINACA);
10. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: ADB-PINACA);
11. 4-methyl-N-ethylcathinone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-MEC; 2-(ethylamino)-1-(4-methylphenyl)propan-1-one);
12. 4-methyl-alpha-pyrrolidinopropiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-MePPP; MePPP; 4-methyl-[alpha]-pyrrolidinopropiophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)propan-1-one);
13. alpha-pyrrolidinopentiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: [alpha]-PVP; [alpha]-pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one);
14. Butylone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one);
15. Pentdrone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: [alpha]-methylaminovalerophenone; 2-(methylamino)-1-phenylpentan-1-one);
16. Pentylone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one);
17. 4-fluoro-N-methylcathinone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-FMC; flephedrone; 1-(4-fluorophenyl)-2-(methylamino)propan-1-one);
18. 3-fluoro-N-methylcathinone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 3-FMC; 1-(3-fluorophenyl)-2-(methylamino)propan-1-one);
19. Naphyrone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: naphthylpyrovalerone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one);
20. alpha-pyrrolidinobutiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: [alpha]-PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one);
21. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (Other name: "AB-CHMINACA");

22. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (Other names: "AB-PINACA");
23. [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (Other name: "THJ-2201");
24. N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (Other name: acetyl fentanyl); and
- \*25. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (common names: MAB-CHMINACA and ABD-CHMINACA).

Changes to the schedules are designated by an asterisk (\*).

TRD-201601369

Lisa Hernandez

General Counsel

Department of State Health Services

Filed: March 22, 2016



### Amendment to the Texas Controlled Substances Schedule

This amendment to the Texas Schedules of Controlled Substances was signed by the Commissioner of the Department of State Health Services, and it will take effect 21 days following publication of this notice in the *Texas Register*.

The Administrator of the Drug Enforcement Administration (DEA) issued a final rule placing 5-[[[(2S-2-amino-3-[4-aminocarbonyl]-2,6-dimethylphenyl]-1-oxopropyl)](1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid (eluxadoline), including its salts, isomers, and salts of isomers into Schedule IV of the United States Controlled Substances Act (CSA) effective December 17, 2015. This final order was published in the Federal Register, Volume 80, Number 218, pages 69861 - 69864. The Administrator has taken action based on the following.

1. Eluxadoline has a low potential for abuse relative to the drugs or other substances in schedule III.
2. Eluxadoline has a currently accepted medical use in treatment in the United States.
3. Abuse of eluxadoline may lead to limited psychological dependence similar to that of schedule IV drugs, but less than that of schedule III drugs.

Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced actions were published in the Federal Register; and, in the capacity as Commissioner of the Texas Department of State Health Services, John Hellerstedt, M.D., does hereby order that the substance 5-[[[(2S-2-amino-3-[4-aminocarbonyl]-2,6-dimethylphenyl]-1-oxopropyl)](1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid (eluxadoline), including its salts, isomers, and salts of isomers be placed into Schedule IV.

### SCHEDULE IV

Schedule IV consists of:

-Schedule IV depressants

\*\*\*

-Schedule IV stimulants

\*\*\*

-Schedule IV narcotics

\*\*\*

-Schedule IV other substances

Unless specifically excepted or unless listed in another schedule, a material, compound, substance's salts:

(1) Butorphanol, including its optical isomers;

(2) Carisoprodol;

\* (3) Eluxadoline (other name: 5-[[[(2S-2-amino-3-[4-aminocarbonyl]-2,6-dimethylphenyl]-1-oxopropyl)](1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) including its salts, isomers, and salts of isomers;

(4) Lorcarserin including its salts, isomers and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible; and

(5) Pentazocine, its salts, derivatives, compounds, or mixtures.

Changes to the schedules are designated by an asterisk (\*).

TRD-201601370

Lisa Hernandez

General Counsel

Department of State Health Services

Filed: March 22, 2016



## Texas Department of Housing and Community Affairs

### 2016 Competitive Housing Tax Credit Application Public Hearing Schedule

Announcement of the Public Hearing Schedule for Comment on the 2016 Competitive Housing Tax Credit Applications

The mission of the Texas Department of Housing and Community Affairs ("the Department") is to administer its assigned programs efficiently, transparently, and lawfully and to invest its resources strategically and develop high quality affordable housing which allows Texas communities to thrive. Through our rental housing programs, the Department encourages the new construction or rehabilitation of high-quality affordable multifamily housing, primarily through private developers. These developments benefit Texans by providing qualified households with safe, affordable, quality housing.

The following seven public hearings are provided to gather public comment on the 2016 Competitive Housing Tax Credit Applications. The schedule of these meetings is provided below:

#### Lubbock

Wednesday, April 6 at 6:00 p.m.

Groves Library Community Room

5520 19th Street

Lubbock, TX 79407

<http://library.ci.lubbock.tx.us/>

#### Dallas

Wednesday, April 13 at 6:00 p.m.

J. Erik Johnson Central Library Auditorium

1515 Young Street